
    
      This open-label study will assess the overall safety and tolerability of 400 mg total daily
      dose centanafadine sustained-release tablets in subjects, over the course of approximately 52
      weeks. This study will accept rollover subjects from both the 405-201-00013 and 405-201-00014
      trials. For individuals that did not participate in one of the studies mentioned above, they
      will be able to enroll if they meet the inclusion criteria as outlined below.
    
  